Results 191 to 200 of about 3,403,053 (289)
Tracking Motor Progression and Device‐Aided Therapy Eligibility in Parkinson's Disease
ABSTRACT Objective To characterise the progression of motor symptoms and identify eligibility for device‐aided therapies in Parkinson's disease, using both the 5‐2‐1 criteria and a refined clinical definition, while examining differences across genetic subgroups.
David Ledingham +7 more
wiley +1 more source
Assessing Video as an Immersive Tool for Teaching and Learning Methods of Attitude, Ethics & Communication (AETCOM) for Undergraduate Medical Students [PDF]
N. Sulekha, M. Neeraj
openalex +1 more source
<i>Journal of Medical Ethics</i> at 50: a data-driven history. [PDF]
Dranseika V +2 more
europepmc +1 more source
ABSTRACT Objective Cognitive impairment, fatigue, and depression are common in multiple sclerosis (MS), potentially due to disruption of regional functional connectivity caused by white matter (WM) lesions. We explored whether WM lesions functionally connected to specific brain regions contribute to these MS‐related manifestations.
Alessandro Franceschini +7 more
wiley +1 more source
Reimagining regulation, placebos and other issues in medical ethics [PDF]
Kenneth Boyd
openalex +1 more source
Quality of life measures in health care and medical ethics [PDF]
Dan W. Brock
openalex +1 more source
ABSTRACT Background Poststroke fatigue (PSF) and frailty share substantial overlap in their manifestations, yet previous research has yielded conflicting results due to the use of heterogeneous frailty assessment tools. Objective To evaluate the independent impact of frailty on PSF using a unified measurement system (Tilburg Frailty Indicator, TFI ...
Chuan‐Bang Chen +6 more
wiley +1 more source
Comment: Reply to Medical ethics of spaceflight should be based on ethical theories and include the non-ethical context. [PDF]
Rajput S, Cole V.
europepmc +1 more source
ABSTRACT Objective Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is a progressive neuromuscular disorder with no approved treatments. Identifying reliable biomarkers is critical to monitor disease severity, activity, and progression. Interleukin‐6 (IL‐6) has been proposed as a candidate biomarker, but longitudinal validation is limited ...
Jonathan Pini +13 more
wiley +1 more source

